Philip Hykin

6.0k total citations · 2 hit papers
104 papers, 4.0k citations indexed

About

Philip Hykin is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Philip Hykin has authored 104 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Ophthalmology, 65 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Molecular Biology. Recurrent topics in Philip Hykin's work include Retinal Diseases and Treatments (86 papers), Retinal Imaging and Analysis (56 papers) and Retinal and Optic Conditions (45 papers). Philip Hykin is often cited by papers focused on Retinal Diseases and Treatments (86 papers), Retinal Imaging and Analysis (56 papers) and Retinal and Optic Conditions (45 papers). Philip Hykin collaborates with scholars based in United Kingdom, Germany and Italy. Philip Hykin's co-authors include Sobha Sivaprasad, Tünde Pető, Anthony J. Bron, Robin Hamilton, Catey Bunce, Catherine Egan, Frank G. Holz, Michel Michaelides, Giovanni Staurenghi and Richard David Leslie and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Ophthalmology.

In The Last Decade

Philip Hykin

101 papers receiving 3.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

2014 464 citations Frank G. Holz, Ramin Tadayoni et al. profile →
A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study)

2010 394 citations Robin Hamilton, Ranjan Rajendram et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip Hykin United Kingdom	33	3.5k	2.6k	507	347	231	104	4.0k
Panagiotis Theodossiadis Greece	32	2.9k 0.8×	2.0k 0.8×	445 0.9×	181 0.5×	109 0.5×	213	3.4k
Andrew A. Moshfeghi United States	30	2.9k 0.8×	1.9k 0.7×	567 1.1×	166 0.5×	165 0.7×	111	3.5k
José Garcia-Arumı́ Spain	39	3.9k 1.1×	2.8k 1.1×	881 1.7×	85 0.2×	260 1.1×	171	4.6k
Armin Wolf Germany	31	2.9k 0.8×	2.0k 0.8×	531 1.0×	134 0.4×	263 1.1×	199	3.6k
Ilkka Immonen Finland	27	1.6k 0.4×	978 0.4×	461 0.9×	417 1.2×	224 1.0×	97	2.5k
Barbara A. Blodi United States	30	3.1k 0.9×	2.0k 0.8×	369 0.7×	97 0.3×	167 0.7×	87	3.4k
Peiquan Zhao China	29	2.1k 0.6×	2.0k 0.8×	909 1.8×	142 0.4×	517 2.2×	230	3.4k
V. Diana United States	33	3.3k 0.9×	1.8k 0.7×	487 1.0×	101 0.3×	172 0.7×	126	3.6k
Jordi Monés Spain	30	2.9k 0.8×	2.2k 0.8×	645 1.3×	66 0.2×	389 1.7×	73	3.5k
Michele Figus Italy	26	1.6k 0.4×	1.1k 0.4×	220 0.4×	445 1.3×	106 0.5×	152	2.4k

Countries citing papers authored by Philip Hykin

Since Specialization

Citations

This map shows the geographic impact of Philip Hykin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Hykin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Hykin more than expected).

Fields of papers citing papers by Philip Hykin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Hykin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Hykin. The network helps show where Philip Hykin may publish in the future.

Co-authorship network of co-authors of Philip Hykin

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Hykin. A scholar is included among the top collaborators of Philip Hykin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Hykin. Philip Hykin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pennington, Becky, Abualbishr Alshreef, Laura Flight, et al.. (2021). Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. PharmacoEconomics. 39(8). 913–927. 6 indexed citations

Hykin, Philip, A Toby Prevost, Sobha Sivaprasad, et al.. (2021). Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technology Assessment. 25(38). 1–196. 12 indexed citations

Wolf, Sebastián, Frank G. Holz, Philip Hykin, et al.. (2021). Neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E): post-hoc analysis of injection intensive (I-I) requirement for patients in the ARIES study. Investigative Ophthalmology & Visual Science. 62(8). 423–423.

Mitchell, Paul, Frank G. Holz, Philip Hykin, et al.. (2020). Comparison of treat-and-extend (T&E) dosing regimens and visual outcomes in the ARIES and ALTAIR studies of intravitreal aflibercept (IVT-AFL) in neovascular age-related macular degeneration (nAMD). Investigative Ophthalmology & Visual Science. 61(7). 4219–4219. 4 indexed citations

Souied, Eric H., Frank G. Holz, Philip Hykin, et al.. (2020). Efficacy of Intravitreal Aflibercept Treat-and-Extend Regimen Over 2 Years for Neovascular Age-Related Macular Degeneration: ARIES Study. Investigative Ophthalmology & Visual Science. 61(7). 4210–4210. 3 indexed citations

Mitchell, Paul, Eric H. Souied, Edoardo Midena, et al.. (2019). Efficacy of Intravitreal Aflibercept Administered using Treat-and-Extend Regimen over 2 Years in Patients with Neovascular Age-Related Macular Degeneration: 1-Year ARIES Results.. Investigative Ophthalmology & Visual Science. 60(9). 117–117. 2 indexed citations

Robson, Anthony G., Philip Hykin, Bishwanath Pal, et al.. (2018). Unilateral pigmentary retinopathy: a retrospective case series. Acta Ophthalmologica. 97(4). e601–e617. 12 indexed citations

Nicholson, Luke, et al.. (2017). Retinal Nonperfusion in the Posterior Pole Is Associated With Increased Risk of Neovascularization in Central Retinal Vein Occlusion. American Journal of Ophthalmology. 182. 118–125. 33 indexed citations

Holz, Frank G., Ramin Tadayoni, Stephen Beatty, et al.. (2016). Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. Eye. 30(8). 1063–1071. 43 indexed citations

10.

Patrao, Namritha, Catherine Egan, Amer Omar, et al.. (2016). Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting. American Journal of Ophthalmology. 172. 51–57. 65 indexed citations

11.

Comyn, Oliver, Luke Nicholson, Philip Hykin, et al.. (2016). Changes in Disorganization of Retinal Inner Layers (DRIL) Predict Retinal Sensitivity in Eyes with Diabetic Macular Edema. Investigative Ophthalmology & Visual Science. 57(12). 1 indexed citations

12.

Nicholson, Luke, Jayashree Ramu, Namritha Patrao, et al.. (2015). The sensitivity and specificity of disorganisation of the retinal inner layers on SD-OCT in detecting capillary nonperfusion in diabetic retinopathy. Investigative Ophthalmology & Visual Science. 56(7). 5940–5940. 1 indexed citations

13.

Comyn, Oliver, Tünde Pető, Catey Bunce, et al.. (2013). The LUCIDATE study: a randomized clinical trial to evaluate the long-term functional and anatomical effects of repeated ranibizumab therapy compared with laser in diabetic macular edema. Investigative Ophthalmology & Visual Science. 54(15). 2390–2390. 1 indexed citations

14.

Comyn, Oliver, Sobha Sivaprasad, Philip Hykin, et al.. (2013). Differences in the topographic profile of retinal thickening in cases of diabetic macular edema with and without serous macular detachment. Investigative Ophthalmology & Visual Science. 54(15). 4928–4928. 1 indexed citations

15.

Comyn, Oliver, et al.. (2012). Repeatability of Spectralis OCT Retinal Thickness and Volume Measurements in Diabetic Macular Oedema. Investigative Ophthalmology & Visual Science. 53(14). 3172–3172. 1 indexed citations

16.

Webster, Andrew R., Anthony G. Robson, Philip Hykin, et al.. (2011). Unilateral Retinitis Pigmentosa? A Retrospective Case Series Of Unilateral Pigmentary Retinopathy. Investigative Ophthalmology & Visual Science. 52(14). 4995–4995. 1 indexed citations

17.

Peters, Swaantje, Ian A. Cree, Robert Alexander, et al.. (2007). Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability. Cytokine. 40(2). 144–150. 66 indexed citations

18.

Patel, J I, Philip Hykin, Vy Luong, et al.. (2005). Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulation. Eye. 20(8). 873–881. 35 indexed citations

19.

Hykin, Philip, et al.. (1996). The efficacy of focal laser treatment in radiation maculopathy. Investigative Ophthalmology & Visual Science. 37(3). 620.

20.

Hykin, Philip, et al.. (1992). Theodor Leber: A founder of ophthalmic research. Survey of Ophthalmology. 37(1). 63–68. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact